Agendia, Imegen Ink Distribution Deal for Breast Cancer Tests in Spain, Portugal

Agendia has signed an agreement with Valencia, Spain-based Imegen for the exclusive distribution of Agendia’s MammaPrint and BluePrint breast cancer genomic tests in Spain and Portugal.

MammaPrint measures the expression of 70 genes and classifies patients as either high risk or low risk of recurrence over a 10-year period. BluePrint is an 80-gene assay that classifies patients as having either basal, luminal, or HER2 subtypes of breast cancer to further guide treatments.

Source: https://www.genomeweb.com/microarrays-multiplexing/agendia-imegen-ink-distribution-deal-breast-cancer-tests-spain-portugal